WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year

Core Insights - WuXi Biologics has been recognized as a 2025 Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics, marking the fifth consecutive year of high ESG Risk Ratings [1][2] - The company ranks in the top 1% of companies assessed in the pharmaceutical industry, highlighting its strong ESG achievements [2] Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics [5] - The company employs over 12,000 skilled employees across multiple countries, including China, the United States, Ireland, Germany, and Singapore [6] ESG Commitment - The company views Environmental, Social, and Governance (ESG) responsibilities as integral to its business strategy and aims to be a leader in the biologics CRDMO sector [7] - WuXi Biologics has made significant progress in its ESG strategy, receiving various accolades such as the MSCI AAA Rating and inclusion in the Dow Jones Sustainability Indices for two consecutive years [3] Achievements and Recognition - The company has been included in the UNGC 20 Case Examples of Sustainable Development and awarded the Platinum Medal by EcoVadis [3] - WuXi Biologics has also been recognized in the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score [3]